Alphatec Holdings reported second-quarter 2026 total revenue of $214 million, a 15% increase year over year, and raised its full-year adjusted EBITDA guidance to approximately $140 million from the prior outlook of $134 million. Surgical revenue grew 17% to $196 million, driven by a 20% rise in surgical case volume and 24% growth in net new surgeons. Adjusted EBITDA reached $36 million, up 53% year over year with a 17% margin, while non-GAAP gross margin expanded 260 basis points to 72.5%. The company generated $1 million in free cash flow, marking its fourth consecutive quarter of positive trailing 12-month free cash flow, and reaffirmed full-year revenue guidance of approximately $882 million and free cash flow of at least $20 million. Management noted that biologics attachment rates stabilized but did not improve as expected, contributing to a 2.7% decline in revenue per case, and highlighted EOS Insight adoption driving a 32% implant revenue lift within six months at accounts using the platform.
Alphatec Holdings IncAlphatec reported 15% revenue growth and raised adjusted EBITDA guidance, indicating strong financial performance.
JPMorgan Chase & Co